Kairos raises $1.56M to cover January payment as cash runs thin
What's the deal? KairosDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotech, raised $1.56 million in gross proceeds through an at-the-market (ATM) equity programme after the close of its fiscal third quarter. The company issued 957,599 shares, lifting its share count 26% to 4.69 million by November 13.
Why now? The raise nearly matches a £1.194 million payment — about $1.6 million — owed to manufacturer Lonza in January. That obligation equals roughly 51% of the $3.1 million in cash Kairos held at September 30.
The numbers: Kairos has no product revenue and used $3.0 million in operating cash over nine months, up 28% year on year. Its net loss rose 23% to $5.0 million, while research and development spending climbed 37% to $2.2 million, all tied to clinical trials.
Management says existing cash may not cover planned needs for the next 12 months and continues to report substantial doubt about its ability to continue as a going concern.
What's the endgame? The money funds ENV-105, Kairos' lead candidate designed to restore sensitivity to existing cancer therapies, positioning it as a complement to established EGFR drugs. The programme includes a Phase 2 prostate trial and a Phase 1 lung trial. A July release reported median progression-free survival above 13 months in the prostate study and no Grade 3 or higher toxicities among 13 lung-cancer patients.
What could go wrong? About $1.1 million of capacity remained under the $4.5 million ATM programme, leaving limited headroom before trial and financing costs. The Q3 report added no clinical update, and the safety finding is not evidence of efficacy. Kairos also ended its Celyn term sheet for CL-273, concentrating more of its development case on ENV-105 and earlier-stage KROS 201.
The signal: The raise is near-term survival financing, not a growth event. For cash-constrained clinical-stage biotechs, dilutive equity drips like this one keep the lights on — but each one trades runway for ownership, and the underlying burn remains.
Read more: panabee.com
Image credit: Generated with Gemini
